Published in Blood on May 21, 2009
In vivo efficacy of platelet-delivered, high specific activity factor VIII variants. Blood (2010) 1.08
Gene therapy for hemophilia. Front Biosci (Landmark Ed) (2015) 0.94
Development of Gene Transfer for Induction of Antigen-specific Tolerance. Mol Ther Methods Clin Dev (2014) 0.93
Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation. Br J Haematol (2011) 0.86
piggyBac-mediated phenotypic correction of factor VIII deficiency. Mol Ther Methods Clin Dev (2014) 0.82
Factor VIII delivered by haematopoietic stem cell-derived B cells corrects the phenotype of haemophilia A mice. Thromb Haemost (2011) 0.82
Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A. Haematologica (2015) 0.82
Delivery of nucleic acid therapeutics by genetically engineered hematopoietic stem cells. Adv Drug Deliv Rev (2010) 0.79
In vitro and In vivo Model Systems for Hemophilia A Gene Therapy. J Genet Syndr Gene Ther (2013) 0.76
Ectopic platelet-delivered factor (F) VIII for the treatment of Hemophilia A: Plasma and platelet FVIII, is it all the same? J Genet Syndr Gene Ther (2011) 0.75
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med (2006) 9.68
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 9.42
Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. Proc Natl Acad Sci U S A (2008) 3.58
Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood (2006) 3.07
Hemophilia A. N Engl J Med (1994) 2.96
Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther (2008) 2.56
Lentiviral vectors for enhanced gene expression in human hematopoietic cells. Mol Ther (2000) 2.01
Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood (2005) 1.82
Handicapped retroviral vectors efficiently transduce foreign genes into hematopoietic stem cells. Proc Natl Acad Sci U S A (1987) 1.81
Bioengineering of coagulation factor VIII for improved secretion. Blood (2004) 1.76
Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood (2003) 1.40
Back to the future: a recent history of haemophilia treatment. Haemophilia (2008) 1.39
Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia (2008) 1.35
Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII. J Biol Chem (1997) 1.32
Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens. Blood (2007) 1.28
Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant (2007) 1.26
Correction of murine hemophilia A by hematopoietic stem cell gene therapy. Mol Ther (2005) 1.25
Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion. J Biol Chem (2003) 1.21
Correction of murine hemophilia A and immunological differences of factor VIII variants delivered by helper-dependent adenoviral vectors. Mol Ther (2007) 1.18
Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis (2004) 1.17
Immune implications of gene therapy for hemophilia. Semin Thromb Hemost (2004) 1.16
Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells. Mol Ther (2004) 1.12
Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther (1993) 1.11
Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Blood (2004) 1.10
Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc Natl Acad Sci U S A (1998) 1.07
Thrombopoietic potential and serial repopulating ability of murine hematopoietic stem cells constitutively expressing interleukin 11. Proc Natl Acad Sci U S A (1996) 1.07
High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells. Blood (2006) 1.05
Progress toward vector design for hematopoietic stem cell gene therapy. Curr Gene Ther (2001) 0.97
Preclinical animal models for hemophilia gene therapy: predictive value and limitations. Semin Thromb Hemost (2004) 0.97
Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice. J Thromb Haemost (2004) 0.95
Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A. Curr Gene Ther (2003) 0.90
A 110-amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells. J Biol Chem (1995) 0.89
Immunobiology of inhibitor development in hemophilia A. Semin Thromb Hemost (2003) 0.89
Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains. J Gene Med (2004) 0.89
Establishing immunological tolerance through the induction of molecular chimerism. Front Biosci (2002) 0.87
Stable gammaretroviral vector expression during embryonic stem cell-derived in vitro hematopoietic development. Mol Ther (2006) 0.87
Reducing the genotoxic potential of retroviral vectors. Methods Mol Biol (2008) 0.84
Progress in the molecular biology of inherited bleeding disorders. Haemophilia (2008) 0.83
Generation and characterization of human hematopoietic cell lines expressing factor VIII. J Hematother Stem Cell Res (2002) 0.81
Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther (2005) 3.49
High-level sustained transgene expression in human embryonic stem cells using lentiviral vectors. Stem Cells (2003) 2.42
HOX and non-HOX homeobox genes in leukemic hematopoiesis. Stem Cells (2002) 1.94
Functional analysis of various promoters in lentiviral vectors at different stages of in vitro differentiation of mouse embryonic stem cells. Mol Ther (2007) 1.76
Does retroviral insertional mutagenesis play a role in the generation of induced pluripotent stem cells? Mol Ther (2008) 1.47
Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood (2003) 1.40
Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling. Oncogene (2003) 1.28
Correction of murine hemophilia A by hematopoietic stem cell gene therapy. Mol Ther (2005) 1.25
Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells. Mol Ther (2004) 1.12
Hematopoietic cell fate and the initiation of leukemic properties in primitive primary human cells are influenced by Ras activity and farnesyltransferase inhibition. Mol Cell Biol (2004) 1.00
Role of the docking protein Gab2 in beta(1)-integrin signaling pathway-mediated hematopoietic cell adhesion and migration. Blood (2002) 1.00
G1/S transcriptional networks modulated by the HOX11/TLX1 oncogene of T-cell acute lymphoblastic leukemia. Oncogene (2005) 0.98
Flow cytometry of fluorescent proteins. Methods (2012) 0.97
Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol (2013) 0.96
TLX1/HOX11-mediated disruption of primary thymocyte differentiation prior to the CD4+CD8+ double-positive stage. Br J Haematol (2006) 0.96
BCL-2 and BCL-XL restrict lineage choice during hematopoietic differentiation. J Biol Chem (2003) 0.96
Acetylation-dependent oncogenic activity of metastasis-associated protein 1 co-regulator. EMBO Rep (2010) 0.95
Multiparameter flow cytometry of fluorescent protein reporters. Methods Mol Biol (2004) 0.95
Bypass of senescence, immortalization, and transformation of human hematopoietic progenitor cells. Stem Cells (2005) 0.95
Specific homeodomain-DNA interactions are required for HOX11-mediated transformation. Blood (2003) 0.93
Overexpression of rab7 enhances the kinetics of antigen processing and presentation with MHC class II molecules in B cells. Int Immunol (2002) 0.92
Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A. Curr Gene Ther (2003) 0.90
Phenotype correction of Fanconi anemia group A hematopoietic stem cells using lentiviral vector. Mol Ther (2003) 0.88
Overview of the HIV-1 Lentiviral Vector System. Curr Protoc Mol Biol (2002) 0.88
Generation of HIV-1-based lentiviral vector particles. Curr Protoc Mol Biol (2002) 0.88
Role of TLX1 in T-cell acute lymphoblastic leukaemia pathogenesis. Br J Haematol (2009) 0.88
Stable gammaretroviral vector expression during embryonic stem cell-derived in vitro hematopoietic development. Mol Ther (2006) 0.87
Immortalization of yolk sac-derived precursor cells. Blood (2002) 0.87
Resistance to fas-induced apoptosis in cells from human atherosclerotic lesions: elevated Bcl-XL inhibits apoptosis and caspase activation. J Vasc Res (2007) 0.85
TLX1 and NOTCH coregulate transcription in T cell acute lymphoblastic leukemia cells. Mol Cancer (2010) 0.85
Transcriptional activation by TLX1/HOX11 involves Gro/TLE corepressors. Biochem Biophys Res Commun (2009) 0.84
Reducing the genotoxic potential of retroviral vectors. Methods Mol Biol (2008) 0.84
Factor VIII delivered by haematopoietic stem cell-derived B cells corrects the phenotype of haemophilia A mice. Thromb Haemost (2011) 0.82
Genetic analysis of the ATG7 gene promoter in sporadic Parkinson's disease. Neurosci Lett (2013) 0.82
Analysis of violet-excited fluorochromes by flow cytometry using a violet laser diode. Cytometry A (2003) 0.81
Detection and enrichment of hematopoietic stem cells by side population phenotype. Methods Mol Biol (2004) 0.81
Retroviral transduction in fetal thymic organ culture. Methods Mol Med (2005) 0.80
Integrative molecular and developmental biology of adult stem cells. Biol Cell (2003) 0.80
A novel and functional variant within the ATG5 gene promoter in sporadic Parkinson's disease. Neurosci Lett (2013) 0.80
Specific pharmacological dimerization of KDR in lentivirally transduced human hematopoietic cells activates anti-apoptotic and proliferative mechanisms. FASEB J (2005) 0.79
SCID repopulating cells derived from unmobilised adult human peripheral blood. Curr Med Res Opin (2004) 0.79
Lentiviral fluorescent protein expression vectors for biotinylation proteomics. Methods Mol Biol (2011) 0.77
Hematopoietic immortalizing function of the NKL-subclass homeobox gene TLX1. Genes Chromosomes Cancer (2010) 0.77
Tissue inhibitor of matrix metalloproteinase-1 overexpression in M1 myeloblasts impairs IL-6-induced differentiation. Oncogene (2004) 0.77
Strategies to insulate lentiviral vector-expressed transgenes. Methods Mol Biol (2010) 0.77
Human immunodeficiency virus type 1-based vectors for gene delivery to human hematopoietic stem cells. Methods Mol Med (2003) 0.76
Apoptotic role of IKK in T-ALL therapeutic response. Mol Cancer Res (2011) 0.76
Somatic stem cell plasticity: to be or not to be. Stem Cells (2002) 0.75
Editorial retraction. Stem Cells (2006) 0.75
Identification of a novel 21bp-insertion variant within the LC3B gene promoter in sporadic Parkinson's disease. Transl Res (2013) 0.75
New feature: stem cells in the news. Stem Cells (2002) 0.75
The tao of hematopoietic stem cells: toward a unified theory of tissue regeneration. ScientificWorldJournal (2002) 0.75
Stem cell bouillabaisse-potpourri. Stem Cells (2002) 0.75
Advancing the fast-paced field of stem cell research: stem cells increases from 6 to 10 issues in its 23rd year of publication. Stem Cells (2005) 0.75